{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T20:51:34Z","timestamp":1763412694090,"version":"3.45.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00520-025-09953-1","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:02:38Z","timestamp":1760158958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Younger age as a risk factor for rash development in pemetrexed and carboplatin treatment with dexamethasone prophylaxis"],"prefix":"10.1007","volume":"33","author":[{"given":"Yoshitaka","family":"Saito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Sakakibara-Konishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"9953_CR1","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s10147-019-01431-z","volume":"24","author":"H Akamatsu","year":"2019","unstructured":"Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y et al (2019) The Japanese lung cancer society guideline for non-small cell lung cancer, stage IV. Int J Clin Oncol 24:731\u2013770","journal-title":"Int J Clin Oncol"},{"key":"9953_CR2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00953-2019","volume":"55","author":"A Scherpereel","year":"2020","unstructured":"Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D et al (2020) ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J 55:1900953","journal-title":"Eur Respir J"},{"key":"9953_CR3","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/j.jtho.2016.05.021","volume":"11","author":"TY Cheng","year":"2016","unstructured":"Cheng TY, Cramb SM, Baade PD, Youlden DR, Nwogu C, Reid ME (2016) The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. J Thorac Oncol 11:1653\u20131671","journal-title":"J Thorac Oncol"},{"key":"9953_CR4","doi-asserted-by":"publisher","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","volume":"5","author":"C Zappa","year":"2016","unstructured":"Zappa C, Mousa SA (2016) Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res 5:288\u2013300","journal-title":"Transl Lung Cancer Res"},{"key":"9953_CR5","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, D\u00f3mine M et al (2023) Pembrolizumab plus pemetrexed and platinum in non-squamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol 41:1992\u20131998","journal-title":"J Clin Oncol"},{"key":"9953_CR6","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1200\/JCO.2012.47.9626","volume":"31","author":"JD Patel","year":"2013","unstructured":"Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR et al (2013) Pointbreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV non-squamous non-small-cell lung cancer. J Clin Oncol 31:4349\u20134357","journal-title":"J Clin Oncol"},{"key":"9953_CR7","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J et al (2021) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 22:198\u2013211","journal-title":"Lancet Oncol"},{"key":"9953_CR8","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1200\/JCO.22.00975","volume":"41","author":"ML Johnson","year":"2023","unstructured":"Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K et al (2023) Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study. J Clin Oncol 41:1213\u20131227","journal-title":"J Clin Oncol"},{"key":"9953_CR9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1001\/jamaoncol.2022.7711","volume":"9","author":"MA Socinski","year":"2023","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Nishio M, Mok TSK, Reck M et al (2023) Association of immune-related adverse events with efficacy of Atezolizumab in patients with non-small cell lung cancer: pooled analyses of the phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials. JAMA Oncol 9:527\u2013535","journal-title":"JAMA Oncol"},{"key":"9953_CR10","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","volume":"3","author":"A Santoro","year":"2008","unstructured":"Santoro A, O\u2019Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M et al (2008) Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona\u00efve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 3:756\u2013763","journal-title":"J Thorac Oncol"},{"key":"9953_CR11","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s10637-013-9941-z","volume":"31","author":"I Okamoto","year":"2013","unstructured":"Okamoto I, Aoe K, Kato T, Hosomi Y, Yokoyama A, Imamura F et al (2013) Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-na\u00efve patients with advanced nonsquamous non-small-cell lung cancer. Invest New Drugs 31:1275\u20131282","journal-title":"Invest New Drugs"},{"key":"9953_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.resinv.2018.09.003","volume":"57","author":"N Nogami","year":"2019","unstructured":"Nogami N, Nishio M, Okamoto I, Enatsu S, Suzukawa K, Takai H et al (2019) Pemetrexed and carboplatin combination therapy followed by pemetrexed maintenance in Japanese patients with non-squamous non-small cell lung cancer: a subgroup analysis of elderly patients. Respir Investig 57:27\u201333","journal-title":"Respir Investig"},{"key":"9953_CR13","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/ajco.13488","volume":"17","author":"M Shinoda","year":"2021","unstructured":"Shinoda M, Shinkai M, Hara Y, Tomaru K, Manabe S, Murakami S et al (2021) Efficacy and safety of carboplatin and pemetrexed followed by maintenance with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer: a single-arm, open-label, multicenter, phase II study. Asia Pac J Clin Oncol 17:486\u2013494","journal-title":"Asia Pac J Clin Oncol"},{"key":"9953_CR14","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1158\/1078-0432.CCR-21-3194","volume":"28","author":"H Hayashi","year":"2022","unstructured":"Hayashi H, Sugawara S, Fukuda Y, Fujimoto D, Miura S, Ota K et al (2022) A randomized phase II study comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-mutated NSCLC with resistance to EGFR tyrosine kinase inhibitors (WJOG8515L). Clin Cancer Res 28:893\u2013902","journal-title":"Clin Cancer Res"},{"key":"9953_CR15","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","volume":"17","author":"CJ Langer","year":"2016","unstructured":"Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF et al (2016) Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 17:1497\u20131508","journal-title":"Lancet Oncol"},{"doi-asserted-by":"crossref","unstructured":"Rusthoven JJ, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B et al (1999) Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17:1194","key":"9953_CR16","DOI":"10.1200\/JCO.1999.17.4.1194"},{"key":"9953_CR17","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1023\/A:1008372529239","volume":"10","author":"C Cripps","year":"1999","unstructured":"Cripps C, Burnell M, Jolivet J, Batist G, Lofters W, Dancey J et al (1999) Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC clinical trials group study. Ann Oncol 10:1175\u20131179","journal-title":"Ann Oncol"},{"key":"9953_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-020-01818-3","volume":"26","author":"K Aogi","year":"2021","unstructured":"Aogi K, Takeuchi H, Saeki T, Aiba K, Tamura K, Iino K et al (2021) Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. Int J Clin Oncol 26:1\u201317","journal-title":"Int J Clin Oncol"},{"key":"9953_CR19","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA et al (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38:2782\u20132797","journal-title":"J Clin Oncol"},{"key":"9953_CR20","first-page":"57","volume":"32","author":"J Herrstedt","year":"2023","unstructured":"Herrstedt J, Clark-Snow R, Ruhlmann CH, Jordan K, Scott\u00e9 F (2023) MASCC\/ESMO antiemetic guidelines: introduction to the 2023 guidelines update. Support Care Cancer 32:57","journal-title":"Support Care Cancer"},{"key":"9953_CR21","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1248\/bpb.b15-00435","volume":"38","author":"T Sakurada","year":"2015","unstructured":"Sakurada T, Kakiuchi S, Tajima S, Horinouchi Y, Konaka K, Okada N et al (2015) Pemetrexed-induced rash may be prevented by supplementary corticosteroids. Biol Pharm Bull 38:1752\u20131756","journal-title":"Biol Pharm Bull"},{"key":"9953_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyab077","volume":"27","author":"T Sakurada","year":"2022","unstructured":"Sakurada T, Nokihara H, Koga T, Zamami Y, Goda M, Yagi K et al (2022) Prevention of pemetrexed-induced rash using low-dose corticosteroids: a phase II study. Oncologist 27:e554\u2013e560","journal-title":"Oncologist"},{"key":"9953_CR23","first-page":"504","volume":"31","author":"Y Saito","year":"2023","unstructured":"Saito Y, Uchiyama K, Takekuma Y, Komatsu Y, Sugawara M (2023) Risk factor analysis for anti-epidermal growth factor receptor monoclonal antibody-induced skin toxicities in real-world metastatic colorectal cancer treatment. Support Care Cancer 31:504","journal-title":"Support Care Cancer"},{"key":"9953_CR24","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1200\/EDBK_289911","volume":"40","author":"A Deutsch","year":"2020","unstructured":"Deutsch A, Leboeuf NR, Lacouture ME, McLellan BN (2020) Dermatologic adverse events of systemic anticancer therapies: cytotoxic chemotherapy, targeted therapy, and immunotherapy. Am Soc Clin Oncol Educ Book 40:485\u2013500","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"9953_CR25","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","volume":"35","author":"JS Weber","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J et al (2017) Safety profile of Nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 35:785\u2013792","journal-title":"J Clin Oncol"},{"key":"9953_CR26","first-page":"769","volume":"2","author":"C Pi\u00e9rard-Franchimont","year":"2011","unstructured":"Pi\u00e9rard-Franchimont C, Quatresooz P, Reginster MA, Pi\u00e9rard GE (2011) Revisiting cutaneous adverse reactions to pemetrexed. Oncol Lett 2:769\u2013772","journal-title":"Oncol Lett"},{"key":"9953_CR27","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40264-021-01135-2","volume":"44","author":"N de Rouw","year":"2021","unstructured":"de Rouw N, Piet B, Derijks HJ, van den Heuvel MM, Ter Heine R (2021) Mechanisms, management and prevention of pemetrexed-related toxicity. Drug Saf 44:1271\u20131281","journal-title":"Drug Saf"},{"key":"9953_CR28","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2020.1010","volume":"14","author":"G Eichhoff","year":"2020","unstructured":"Eichhoff G (2020) Slowly developing toxic epidermal necrolysis-like reaction associated with pemetrexed and carboplatin. Ecancermedicalscience 14:1010","journal-title":"Ecancermedicalscience"},{"key":"9953_CR29","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2174\/157488612805076543","volume":"7","author":"C Pierard-Franchimont","year":"2012","unstructured":"Pierard-Franchimont C, Lesuisse M, Humbert P, Delvenne P, Pierard GE (2012) Toxic epidermal necrolysis and antifolate drugs in cancer chemotherapy. Curr Drug Saf 7:357\u2013360","journal-title":"Curr Drug Saf"},{"key":"9953_CR30","first-page":"AB11","volume":"72","author":"C Gutierrez Garcia-Rodrigo","year":"2015","unstructured":"Gutierrez Garcia-Rodrigo C, Menis D, Sanz-Motilva VHL, Larrain H, Ortiz de Frutos J, Vanaclocha SF (2015) Pemetrexed-related cytotoxic skin reaction. J Am Acad Dermatol 72:AB11","journal-title":"J Am Acad Dermatol"},{"key":"9953_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000229751","volume":"77","author":"A Jatoi","year":"2009","unstructured":"Jatoi A, Green EM, Rowland KM Jr, Sargent DJ, Alberts SR (2009) Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in North Central Cancer Treatment Group study N0147. Oncology 77:120\u2013123","journal-title":"Oncology"},{"key":"9953_CR32","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1006\/excr.1996.0274","volume":"227","author":"WR Reenstra","year":"1996","unstructured":"Reenstra WR, Yaar M, Gilchrest BA (1996) Aging affects epidermal growth factor receptor phosphorylation and traffic kinetics. Exp Cell Res 227:252\u2013255","journal-title":"Exp Cell Res"},{"issue":"Suppl 2","key":"9953_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-018-0289-y","volume":"14","author":"R Warrington","year":"2018","unstructured":"Warrington R, Silviu-Dan F, Wong T (2018) Drug allergy. Allergy Asthma Clin Immunol 14(Suppl 2):60","journal-title":"Allergy Asthma Clin Immunol"},{"key":"9953_CR34","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.1158\/1078-0432.CCR-07-5143","volume":"14","author":"Y Ohe","year":"2008","unstructured":"Ohe Y, Ichinose Y, Nakagawa K, Tamura T, Kubota K, Yamamoto N et al (2008) Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 14:4206\u20134212","journal-title":"Clin Cancer Res"},{"key":"9953_CR35","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/sj.bjc.6603321","volume":"95","author":"K Nakagawa","year":"2006","unstructured":"Nakagawa K, Kudoh S, Matsui K, Negoro S, Yamamoto N, Latz JE et al (2006) A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. Br J Cancer 95:677\u2013682","journal-title":"Br J Cancer"},{"key":"9953_CR36","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/JTO.0000000000000111","volume":"9","author":"M Patki","year":"2014","unstructured":"Patki M, Gadgeel S, Huang Y, McFall T, Shields AF, Matherly LH et al (2014) Glucocorticoid receptor status is a principal determinant of variability in the sensitivity of non-small-cell lung cancer cells to pemetrexed. J Thorac Oncol 9:519\u2013526","journal-title":"J Thorac Oncol"},{"key":"9953_CR37","first-page":"372","volume":"31","author":"Y Saito","year":"2023","unstructured":"Saito Y, Takekuma Y, Takeshita T, Oshino T, Sugawara M (2023) Dexamethasone dose-dependently prevents taxane-associated acute pain syndrome in breast cancer treatment. Support Care Cancer 31:372","journal-title":"Support Care Cancer"},{"key":"9953_CR38","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2217\/fon.14.251","volume":"11","author":"Y Kobayashi","year":"2015","unstructured":"Kobayashi Y, Komatsu Y, Yuki S, Fukushima H, Sasaki T, Iwanaga I et al (2015) Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP. Future Oncol 11:617\u2013627","journal-title":"Future Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09953-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09953-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09953-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T19:05:44Z","timestamp":1763406344000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09953-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["9953"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09953-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2025,10,11]]},"assertion":[{"value":"20 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study were carried out in accordance with the ethical standards of the institutional and\/or national research committee and the 1964 Helsinki Declaration and its later amendments, or comparable ethical standards. This study was approved by the Ethical Review Board for Life Science and Medical Research of Hokkaido University Hospital (approval number: 023-0213). Given the retrospective nature of the study, the requirement for informed consent from the participants was waived by the Ethical Review Board for Life Science and Medical Research of Hokkaido University Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"932"}}